These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 25259718

  • 1. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.
    Endocrinology; 2014 Dec; 155(12):4785-97. PubMed ID: 25259718
    [Abstract] [Full Text] [Related]

  • 2. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ.
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [Abstract] [Full Text] [Related]

  • 3. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X, Ominsky MS, Villasenor KS, Niu QT, Asuncion FJ, Xia X, Grisanti M, Wronski TJ, Simonet WS, Ke HZ.
    Endocrinology; 2018 Jan 01; 159(1):260-271. PubMed ID: 29069393
    [Abstract] [Full Text] [Related]

  • 4. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X, Jee WS, Li X, Paszty C, Ke HZ.
    Bone; 2011 Feb 01; 48(2):197-201. PubMed ID: 20850580
    [Abstract] [Full Text] [Related]

  • 5. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
    Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    Endocrinology; 2011 Sep 01; 152(9):3312-22. PubMed ID: 21733832
    [Abstract] [Full Text] [Related]

  • 6. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
    Ma YL, Hamang M, Lucchesi J, Bivi N, Zeng Q, Adrian MD, Raines SE, Li J, Kuhstoss SA, Obungu V, Bryant HU, Krishnan V.
    Bone; 2017 Apr 01; 97():20-28. PubMed ID: 27939957
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
    Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ.
    J Bone Miner Res; 2010 Dec 01; 25(12):2647-56. PubMed ID: 20641040
    [Abstract] [Full Text] [Related]

  • 8. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
    Liu Y, Rui Y, Cheng TY, Huang S, Xu L, Meng F, Lee WY, Zhang T, Li N, Li C, Ke H, Li G.
    Calcif Tissue Int; 2016 Mar 01; 98(3):263-74. PubMed ID: 26603303
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats.
    Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK.
    Exp Anim; 2006 Jul 01; 55(4):357-67. PubMed ID: 16880683
    [Abstract] [Full Text] [Related]

  • 10. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ, Bu SY, Wang Y, Rendina E, Lim YF, Marlow D, Clarke SL, Cullen DM, Lucas EA.
    Bone; 2014 Jan 01; 58():151-9. PubMed ID: 24125756
    [Abstract] [Full Text] [Related]

  • 11. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.
    J Bone Miner Res; 2009 Apr 01; 24(4):578-88. PubMed ID: 19049336
    [Abstract] [Full Text] [Related]

  • 12. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW.
    Bone; 2015 Dec 01; 81():380-391. PubMed ID: 26261096
    [Abstract] [Full Text] [Related]

  • 13. Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.
    Takeda S, Sakai S, Shiraishi A, Koike N, Mihara M, Endo K.
    Bone; 2013 Mar 01; 53(1):167-73. PubMed ID: 23232307
    [Abstract] [Full Text] [Related]

  • 14. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
    Ominsky MS, Stouch B, Schroeder J, Pyrah I, Stolina M, Smith SY, Kostenuik PJ.
    Bone; 2011 Aug 01; 49(2):162-73. PubMed ID: 21497676
    [Abstract] [Full Text] [Related]

  • 15. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K.
    Bone; 2008 Nov 01; 43(5):894-900. PubMed ID: 18687415
    [Abstract] [Full Text] [Related]

  • 16. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
    Yao W, Dai W, Jiang L, Lay EY, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE.
    Osteoporos Int; 2016 Jan 01; 27(1):283-294. PubMed ID: 26384674
    [Abstract] [Full Text] [Related]

  • 17. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J, Cai XH, Qin XX, Liu YX.
    Z Gerontol Geriatr; 2018 Jul 01; 51(5):550-556. PubMed ID: 28364259
    [Abstract] [Full Text] [Related]

  • 18. Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats.
    Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK.
    J Nutr Sci Vitaminol (Tokyo); 2006 Feb 01; 52(1):1-8. PubMed ID: 16637224
    [Abstract] [Full Text] [Related]

  • 19. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis.
    Virdi AS, Irish J, Sena K, Liu M, Ke HZ, McNulty MA, Sumner DR.
    J Bone Joint Surg Am; 2015 Jan 21; 97(2):133-40. PubMed ID: 25609440
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats.
    McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Liu M, Ke HZ, Little DG.
    J Orthop Res; 2012 Oct 21; 30(10):1541-8. PubMed ID: 22457198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.